The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution

Expert Opinion on Biological Therapy

Volumn 10, Issue 1, 2010, Pages 113-125

  Herbert, Kirsten E ^a   Prince, H Miles ^a,b,c   Ritchie, David S ^a,b   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Aplastic anaemia; Granulocyte colony stimulating factor; Hematopoietic stem cell mobilization; Non engraftment; Plerixafor; Stem cell factor; Transplantation

Indexed keywords

ANCESTIM; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; NITROSOUREA DERIVATIVE; PLERIXAFOR; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 6; RECOMBINANT STEM CELL FACTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ALLOGENEIC STEM CELL TRANSPLANTATION; APHERESIS; APLASTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW DEPRESSION; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; ERYTHEMA; FEVER; FLUID RETENTION; FLUSHING; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; MAST CELL DEGRANULATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NOSE CONGESTION; OVARY CANCER; PRURITUS; RASH; REVIEW; SIDE EFFECT; SORE THROAT; STEM CELL MOBILIZATION; THROAT TIGHTNESS; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WHEEZING;

ANIMALS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; STEM CELL FACTOR;

EID: 72449136688     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903473123     Document Type: Review

References (105)

1. Simmons DL, Satterthwaite AB, Tenen DG, Seed B. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol 1992;148(1):267-271
2. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation part I-CIBMTR summary slides. CIBMTR Newsl [serial online] 2007;13(2):5-9
3. Harousseau JL, Attal M, Divine M, et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995;15(6):963-969
4. To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9(4):277-284
5. Gorin NC, Labopin M, Blaise D, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009;27(24):3987-3993
6. Levesque JP, Takamatsu Y, Nilsson SK, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001;98(5):1289-1297
7. Levesque JP, Hendy J, Takamatsu Y, et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002;30(5):440-449
8. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/ progenitor cell mobilization. Blood 2004;103(5):1580-1585
9. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111(2):187-196
10. Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001;19(1):37-45 (Pubitemid 32057970)
11. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3(7):687-694
12. Miflin G, Charley C, Stainer C, et al. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Hematol 1996;95(2):345-348
13. Tabilio A, Falzetti F, Giannoni C, et al. Stem cell mobilization in normal donors. J Hematother 1997;6(3):227-234
14. Luider J, Brown C, Selinger S, et al. Factors influencing yields of progenitor cells for allogeneic transplantation: optimization of G-CSF dose, day of collection, and duration of leukapheresis. J Hematother 1997;6(6):575-580
15. Nowrousian MR, Waschke S, Bojko P, et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003; 14:(Suppl 1):i29-36
16. Prosper F, Sola C, Hornedo J, et al. Mobilization of peripheral blood progenitor cells with a combination ofcyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 2003;17(2):437-441
17. Magagnoli M, Sarina B, Balzarotti M, et al. Mobilizing potential of ifosfamide/ vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001;28(10):923-927
18. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98(7):2059-2064
19. Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001;27:(Suppl 2):S23-9
20. Fischmeister G, Kurz M, Haas OA, et al. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Ann Hematol 1999;78(3):117-123
21. Sohn SK, Kim JG, Seo KW, et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30(2):81-86
22. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15(1):19-29, discussion 18
23. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85(1):275-282
24. Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81(7):1709-1719
25. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002;9(3):190-198
26. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9(9):1144-1150
27. Parajuli P, Mosley RL, Pisarev V, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001;29(10):1185-1193
28. Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol 2003;170(11):5511-5522
29. Stadtmauer EA, Schneider CJ, Silberstein LE. Peripheral blood progenitor cell generation and harvesting. Semin Oncol 1995;22(3):291-300
30. Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996;17(6):937-941
31. Lie AK, Rawling TP, Bayly JL, To LB. Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of hemopoietic growth factor and chemotherapy. Br J Hematol 1996;95(1):39-44
32. Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007;40(2):111-118
33. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992 Winter;1(4):329-341
34. Villalon L, Odriozola J, Larana JG, et al. Autologous peripheral blood progenitor cell transplantation with 2 x 10(6)CD34 (+)/kg: an analysis of variables concerning mobilisation and engraftment. Hematol J 2000; 1(6):374-381
35. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18(6):1360-1377
36. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84(3):950-956
37. Roberts AW, DeLuca E, Begley CG, et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995;13(5):512-516
38. Geiger H, Szilvassy SJ, Ragland P, Van Zant G. Genetic analysis of progenitor cell mobilization by granulocyte colony-stimulating factor: verification and mechanisms for loci on murine chromosomes 2 and 11. Exp Hematol 2004;32(1):60-67
39. De Haan G, Ausema A, Wilkens M, et al. Efficient mobilization of hematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Hematol 2000;110(3):638-646
40. De Haan G, Van Zant G. Intrinsic and extrinsic control of hemopoietic stem cell numbers: mapping of a stem cell gene. J Exp Med 1997;186(4):529-536
41. Roberts AW, Foote S, Alexander WS, et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 1997;89(8):2736-2744
42. Prince HM, Imrie K, Sutherland DR, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Hematol 1996;93(1):142-145
43. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14(9):1045-1056
44. Morgan S, Seymour JF, Grigg A, et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previouslytreated with fludarabine. Leukemia 2004;18:1034-1038
45. Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000;37(1-2):157-161
46. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Hematol 2000;108(3):595-601
47. Vantelon JM, Koscielny S, Brault P, et al. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000;25(5):495-499
48. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Hematol 1998;103(1):235-242
49. Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990;63(1):195-201
50. Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148(3):772-777
51. McNiece IK, Zsebo KM. The role of stem cell factor in the hematopoietic system. Cancer Invest 1993;11(6):724-729
52. Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992;80(9):2237-2245
53. Morstyn G, Brown S, Gordon M, et al. Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 1994;51(2):205-214 (Pubitemid 24056522)
54. Montero JC, Lopez-Perez R, San Miguel JF, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Hematologica 2008;93(6):851-859
55. Lemoli RM, Fortuna A. C-kit ligand (SCF) in human multiple myeloma cells. Leuk Lymphoma 1996;20(5-6):457-464
56. Pruneri G, Ponzoni M, Ferreri AJ, et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 2006;48(5):529-535
57. Kraj M, Poglod R, Kopec-Szlezak J, et al. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004;45(11):2281-2289 (Pubitemid 39504323)
58. Wang C, Curtis JE, Geissler EN, et al. The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 1989;3(10):699-702
59. Choe YS, Kim JG, Sohn SK, et al. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma 2006;47(2):267-270
60. Toksoz D, Zsebo KM, Smith KA, et al. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 1992;89(16):7350-7354
61. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63(1):213-224
62. Glaspy J, Davis MW, Parker WR, et al. Biology and clinical potential of stem-cell factor. Cancer Chemother Pharmacol 1996;38(Suppl):S53-7
63. Amgen, Inc. Thousand Oaks C, USA. Product monograph Stemgen; 2004
64. Bernstein ID, Andrews RG, Zsebo KM. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 1991;77(11):2316-2321
65. Lowry PA, Deacon D, Whitefield P, et al. Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors". Blood 1992;80(3):663-669
66. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991;19(3):226-231
67. Koller MR, Bender JG, Miller WM, Papoutsakis ET. Expansion of primitive human hematopoietic progenitors in a perfusion bioreactor system with IL-3, IL-6, and stem cell factor. Biotechnology (NY) 1993;11(3):358-363
68. Duarte RF, Franf DA. The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma 2002;43(6):1179-1187
69. Zsebo KM, Smith KA, Hartley CA, et al. Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci USA 1992;89(20):9464-9468
70. Andrews RG, Knitter GH, Bartelmez SH, et al. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 1991;78(8):1975-1980
71. Andrews RG, Bensinger WI, Knitter GH, et al. The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. Blood 1992;80(11):2715-2720
72. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997;90(8):2939-2951
73. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993;82(6):1720-1723
74. Molineux G, Migdalska A, Szmitkowski M, et al. The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocytecolony-stimulating factor. Blood 1991;78(4):961-966
75. De Revel T, Appelbaum FR, Storb R, et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994;83(12):3795-3799
76. Andrews RG, Briddell RA, Knitter GH, et al. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995;85(1):15-20
77. Yan XQ, Briddell R, Hartley C, et al. Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 1994;84(3):795-799
78. Roberts MM, Swart BW, Simmons PJ, et al. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Br J Hematol 1999;104(4):778-784
79. Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999;93(8):2491-2501
80. Hess DA, Levac KD, Karanu FN, et al. Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood 2002;100(3):869-878
81. Hematti P, Tuchman S, Larochelle A, et al. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells 2004;22(6):1062-1069
82. Hematti P, Sellers SE, Agricola BA, et al. Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates. Blood 2003;101(6):2199-2205
83. Demetri G, Costa J, Hayes D, et al. A Phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre-and post- chemotherapy (CHEMO) with cyclophosphamide (C) and doxorubicin (A) [abstract 367]. Proc Am Soc Clin Oncol 1993;12:142
84. Crawford J, Lau R, Erwin R, et al. A Phase I trial of recombinant methionyl human stem cell factor (SCF) in patients (pts) with advanced non-small cell lung carcinoma (NSCLC) [abstract 338]. Proc Am Soc Clin Oncol 1993;12:135
85. Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996;183(6):2681-2686
86. Weaver A, Chang J, Wrigley E, et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998;16(8):2601-2612
87. Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients-Results of a Phase I/II trial. Blood 1997;89(9):3136-3147
88. Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26(5):471-481
89. Facon T, Harousseau J-L, Maloisel F, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999;94(4):1218-1225
90. Glaspy J, McNiece I, Lemaistre F, et al. Effects of stem cell factor (rhSCF) and Filgrastim (rhG-CSF)on mobilization of peripheral blood progenitor cells (PBPC) and on hematological recovery post-transplant: early results from a Phase I/II study [abstract 76]. Proc Am Soc Clin Oncol 1994;13:68
91. Herbert KE, Morgan S, Prince HM, et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2009;23(2):305-312
92. Dawson MA, Schwarer AP, Muirhead JL, et al. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005;36(5):389-396
93. To LB, Bashford J, Durrant S, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003;31(5):371-378
94. Kurzrock R, Paquette RL, Gratwohl A, et al. Use of stem cell factor (Stemgen(R), SCF) and filgrastim (G-CSF) in aplastic anaemia (AA) patients (pts) who have failed ATG/ALG therapy [abstract 762]. Blood 1997;Suppl 1:173a
95. Schrezenmeier H, Rio B, Camitta B, et al. A randomized controlled study of ancestim (r-met human stem cell factor, SCF) in newly diagnosed severe or very severe aplastic anaemia patients receiving antithymocyte globulin, cycosporine A and filgrastim. Bone Marrow Transplant 2001;27(S1):S64
96. Wadhwa PD, Lazarus HM, Koc ON, et al. Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration. Leuk Res 2003;27(3):215-220
97. Blaise D, Faucher C, Vey N, et al. Rescue of hemopoiesis by a combination of growth factors including stem-cell factor. Lancet 2000;356(9238):1325-1326
98. Korper S, Hutter G, Blau W, et al. Successful treatment of partial graft failure after matched unrelated donor stem cell transplantation by a combination of ancestim (stem cell factor) and granulocyte colony stimulating factor in a patient withheavily pre-treated chronic lymphocytic leukemia. Leuk Lymphoma 2008:1-3
99. Da Silva MG, Pimentel P, Carvalhais A, et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant 2004;34(8):683-691
100. Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999;23:(Suppl 2):S13-9
101. Watts MJ, Sullivan AM, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 1998;16(4):1554-1560
102. Fowler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009;43(12):909-917
103. Chin-Yee IH, Keeney M, Stewart AK, et al. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets. Bone Marrow Transplant 2002;30(12):851-860
104. Mijovic A, Russell N, Clark RE, et al. Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation. Bone Marrow Transplant 2005;35(10):1019, author reply 1020
105. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279(30):31655-31663